Histopathological Patterns of Interstitial Lung Disease: A Multidisciplinary Approach to Distinguishing the Most Common Forms of Lung Fibrosis

By clicking the continue button above, I certify that I have read the CME information below.

Release Date: January 17, 2018
Expiration Date: January 17, 2019

Program Overview
Patients with interstitial lung disease (ILD) continue to suffer unacceptable delays in diagnosis and treatment initiation. Making an early and accurate diagnosis of ILD and its cause is key to initiating appropriate treatment and improving patient outcomes. This activity will use a case-based approach to address knowledge and practice gaps in ILD presentations and diagnoses, as well as to show the importance of a multidisciplinary care team for accurately diagnosing and monitoring ILD and providing and enhancing patient support.


 Brandon T. Larsen, MD, PhD
 Senior Associate Consultant and Assistant Professor
 Department of Laboratory Medicine and Pathology
 Mayo Clinic Arizona
 Scottsdale, AZ

Brandon T. Larsen, MD, PhD completed his medical and graduate school training at the Medical College of Wisconsin, a residency in anatomic pathology at the University of Arizona, and back-to-back fellowships in cardiovascular pathology and pulmonary pathology at Mayo Clinic. After a two-year stint on staff at the University of Arizona, Dr. Larsen returned to Mayo Clinic in Arizona in 2016 as a Senior Associate Consultant, where he currently holds the rank of Assistant Professor in the Department of Laboratory Medicine and Pathology. He enjoys a diverse practice in pulmonary, cardiac, and bone and soft-tissue pathology, as well as general surgical pathology and autopsy. He curates the Charles B. Carrington Memorial Pulmonary Pathology Teaching Collection, one of the largest collections of pulmonary pathology cases in the world. His research interests include surgical pathology and biomarkers of interstitial lung disease, pulmonary infections, and cardiovascular disease, as well as pulmonary, cardiac, and soft-tissue neoplasia. 

Dr. Larsen serves as a Section Editor in Pulmonary Pathology for the Archives of Pathology and Laboratory Medicine, and is a Councilor on the Executive Committee of the Society for Cardiovascular Pathology. He also serves on the Pathology Council of the International Society for Heart and Lung Transplantation and on the House of Delegates of the College of American Pathologists. Dr. Larsen has lectured nationally and internationally on a broad range of clinical and basic-research topics in both pulmonary and cardiovascular pathology, and has authored several dozen peer-reviewed publications and numerous book chapters in these areas.

 Joseph Lasky, MD
 Deming Internal Medicine Endowed Chair
 Professor of Medicine
 Section Chief of Pulmonary Disease
 Critical Care and Environmental Medicine
 Tulane University Health Sciences Center
                      New Orleans, LA

Joseph Lasky, MD earned his medical degree at the University of Minnesota in Minneapolis. He then completed his internship and residency in internal medicine at the Mayo Clinic. Dr. Lasky attended Duke University in Durham, NC, for a fellowship in pulmonary and critical care. During his fellowship, he acquired the skills for basic science research at the National Institute of Environmental Health Science. He is currently a Tenured Professor of Medicine and the Pulmonary/Critical Care Section Chief at Tulane University Medical School.

Dr. Lasky is board-certified in internal medicine and pulmonary diseases. He is a member of the American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.

Dr. Lasky’s main clinical and basic-science research interest is the study of pulmonary fibrosis. Dr. Lasky has served as the Principal Investigator for studies pertaining to lung fibrosis and is a Steering Committee member of the National Institutes of Health’s IPFnet. He is engaged in designing, conducting, and monitoring clinical lung studies. He has been involved in writing medical society guidelines for the care of patients with lung fibrosis and with assisting/advising the Pulmonary Fibrosis Foundation.

Educational Objectives
At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Recognize the clinical features of ILD and differentiate histological patterns of lung fibrosis common in IPF, CTD-ILD, and chronic HP, distinguishing IPF from other pulmonary conditions
  • Recognize the importance and limitations of multidisciplinary discussion in the diagnosis of fibrotic interstitial lung diseases

Target Audience
This activity is intended for community-based pathologists, pulmonologists, and other healthcare professionals involved in the care of patients with ILD. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: contact@potomacme.org.

Disclosure Information
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

Program Faculty

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Brandon T. Larsen, MD, PhD: Consultant/Independent Contractor: Veracyte, Inc.

Joseph Lasky, MD: Speaker’s Bureau: Boehringer Ingelheim, Genentech

Non-faculty Content Contributors

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Kathy Merlo; Blair St. Amand; Lindsay Scott, PT, DPT, ATC: Nothing to disclose

FDA Disclosure
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the posttest and evaluation. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the posttest.  Participant is allowed to take the posttest multiple times.

Jointly provided by Potomac Center for Medical Education and Rockpointe


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.